TRINITY BIOTECH PLC
About TRINITY BIOTECH PLC
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $13.5M
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.5M
- Dividend yield
- 32.35%
- Shares outstanding
- 19.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 21, 1992
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Trading 64% below its 52-week high.
- Pays a dividend yielding about 32.35% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TRINITY BIOTECH PLC.
Write a review
News about TRINITY BIOTECH PLC
News & sentiment via Polygon.io
